董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Igor Krol | 男 | Director | 44 | 7.86万美元 | 未持股 | 2017-06-09 |
| Irackly Mtibelishvily | 男 | Director | 45 | 10.60万美元 | 未持股 | 2017-06-09 |
| Jeffrey D. Abbey | 男 | President, Chief Executive Officer and Director | 55 | 185.49万美元 | 未持股 | 2017-06-09 |
| Hubert Birner | 男 | Chairman of the Board of Directors | 51 | 9.31万美元 | 未持股 | 2017-06-09 |
| Sander van Deventer | 男 | Director | 62 | 6.35万美元 | 未持股 | 2017-06-09 |
| Robert F. Carey | 男 | Director | 59 | 6.87万美元 | 未持股 | 2017-06-09 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Richard D. Katz | -- | Vice President and Chief Financial Officer | 53 | 未披露 | 未持股 | 2017-06-09 |
| Jeffrey D. Abbey | 男 | President, Chief Executive Officer and Director | 55 | 185.49万美元 | 未持股 | 2017-06-09 |
| Lori R. Harrelson | 女 | Vice President of Finance | 47 | 13.03万美元 | 未持股 | 2017-06-09 |
| Charles A. Nicolette | 男 | Chief Scientific Officer and Vice President of Research and Development | 54 | 117.85万美元 | 未持股 | 2017-06-09 |
| Richard D. Katz | 男 | Vice President and Chief Financial Officer | 53 | 未披露 | 未持股 | 2017-06-09 |
董事简历
中英对照 | 中文 | 英文- Igor Krol
-
Igor Krol自2016年6月起担任董事会成员。加入Veset之前，Krol先生在Sberbank CIB和Citigroup Investment Banking从事了12年的投资银行业务。从2001年到2012年，Krol先生在花旗集团（Citigroup）与广泛的全球和新兴市场客户合作，专注于并购和资本市场交易的发起和执行，包括PharmStandard的首次公开募股，这是一家领先的俄罗斯制药公司。Krol先生仍然在PharmStandard（我们的主要股东之一）担任顾问职务。在担任这些职位之前，从1996年到1999年，Krol先生在雀巢公司（Nestle）工作，这是一家全球领先的消费公司，担任不同的职位，包括财务和采购。Krol先生拥有法国枫丹白露欧洲工商管理学院（INSEAD）工商管理硕士学位，以及俄罗斯莫斯科Mirea Technical University系统工程学士学位。
Igor Krol has been a member of the board of directors since June 2016. Prior to joining Veset, Mr. Krol spent 12 years in investment banking at Sberbank CIB and Citigroup Investment Banking. While at Citigroup from 2001 to 2012 Mr. Krol worked with a broad range of global and emerging markets clients focusing on M&A and capital markets deal origination and execution including the initial public offering for Pharmstandard, the leading Russian pharmaceutical company. Mr. Krol still maintains an advisory role with Pharmstandard, one of our principal stockholders. Prior to those roles, Mr. Krol worked at Nestle, the leading global consumer company in varying roles including finance and purchasing between 1996 and 1999. Mr. Krol holds an MBA degree from INSEAD, Fontainebleau, France, and BA in Systems Engineering from MIREA Technical University, Moscow, Russia. - Igor Krol自2016年6月起担任董事会成员。加入Veset之前，Krol先生在Sberbank CIB和Citigroup Investment Banking从事了12年的投资银行业务。从2001年到2012年，Krol先生在花旗集团（Citigroup）与广泛的全球和新兴市场客户合作，专注于并购和资本市场交易的发起和执行，包括PharmStandard的首次公开募股，这是一家领先的俄罗斯制药公司。Krol先生仍然在PharmStandard（我们的主要股东之一）担任顾问职务。在担任这些职位之前，从1996年到1999年，Krol先生在雀巢公司（Nestle）工作，这是一家全球领先的消费公司，担任不同的职位，包括财务和采购。Krol先生拥有法国枫丹白露欧洲工商管理学院（INSEAD）工商管理硕士学位，以及俄罗斯莫斯科Mirea Technical University系统工程学士学位。
- Igor Krol has been a member of the board of directors since June 2016. Prior to joining Veset, Mr. Krol spent 12 years in investment banking at Sberbank CIB and Citigroup Investment Banking. While at Citigroup from 2001 to 2012 Mr. Krol worked with a broad range of global and emerging markets clients focusing on M&A and capital markets deal origination and execution including the initial public offering for Pharmstandard, the leading Russian pharmaceutical company. Mr. Krol still maintains an advisory role with Pharmstandard, one of our principal stockholders. Prior to those roles, Mr. Krol worked at Nestle, the leading global consumer company in varying roles including finance and purchasing between 1996 and 1999. Mr. Krol holds an MBA degree from INSEAD, Fontainebleau, France, and BA in Systems Engineering from MIREA Technical University, Moscow, Russia.
- Irackly Mtibelishvily
-
Irackly Mtibelishvily自2016年以来一直担任我们的董事会成员。Mtibelishvily先生从1998年开始担任花旗集团（Citigroup）的多个职位。2012年至今，Mtibelishvily先生担任俄罗斯和独联体企业和投资银行业务的董事总经理兼董事长，并于2015年12月被任命为中东欧中东和非洲企业和投资银行业务的董事长。在这个职位上，他负责监督和发展花旗集团在超过35个国家的企业和投资银行业务。Mtibelishvily先生是企业融资、资本市场、证券和并购方面的专家。在加入Citigroup之前，Mtibelishvily先生从1994年到1998年在跨国律师事务所Clifford Chance LLP任职。Mtibelishvily先生在莫斯科国立国际关系学院获得国际法律研究硕士学位，在弗吉尼亚大学法学院获得法学硕士学位。
Irackly Mtibelishvily has served as a member of our board of directors since 2016. Since 1998 Mr. Mtibelishvily has served in several capacities for Citigroup. During the period from 2012 until the present, Mr Mtibelishvily has held the position of managing director and chairman of corporate and investment banking for Russia and CIS and in December 2015 was appointed chairman of corporate and investment banking for Central and Eastern Europe Middle East and Africa. In this capacity he is responsible for overseeing and developing Citigroup's corporate and investment banking business in more than 35 countries. Mr. Mtibelishvily is a specialist in corporate finance, capital markets, securities, and mergers and acquisitions. Prior to Citigroup, Mr. Mtibelishvily was with the multinational law firm Clifford Chance LLP from 1994 to 1998. Mr. Mtibelishvily earned a master of international legal studies degree from the Moscow State Institute of International Relations and a master of laws degree from the University of Virginia Law School. - Irackly Mtibelishvily自2016年以来一直担任我们的董事会成员。Mtibelishvily先生从1998年开始担任花旗集团（Citigroup）的多个职位。2012年至今，Mtibelishvily先生担任俄罗斯和独联体企业和投资银行业务的董事总经理兼董事长，并于2015年12月被任命为中东欧中东和非洲企业和投资银行业务的董事长。在这个职位上，他负责监督和发展花旗集团在超过35个国家的企业和投资银行业务。Mtibelishvily先生是企业融资、资本市场、证券和并购方面的专家。在加入Citigroup之前，Mtibelishvily先生从1994年到1998年在跨国律师事务所Clifford Chance LLP任职。Mtibelishvily先生在莫斯科国立国际关系学院获得国际法律研究硕士学位，在弗吉尼亚大学法学院获得法学硕士学位。
- Irackly Mtibelishvily has served as a member of our board of directors since 2016. Since 1998 Mr. Mtibelishvily has served in several capacities for Citigroup. During the period from 2012 until the present, Mr Mtibelishvily has held the position of managing director and chairman of corporate and investment banking for Russia and CIS and in December 2015 was appointed chairman of corporate and investment banking for Central and Eastern Europe Middle East and Africa. In this capacity he is responsible for overseeing and developing Citigroup's corporate and investment banking business in more than 35 countries. Mr. Mtibelishvily is a specialist in corporate finance, capital markets, securities, and mergers and acquisitions. Prior to Citigroup, Mr. Mtibelishvily was with the multinational law firm Clifford Chance LLP from 1994 to 1998. Mr. Mtibelishvily earned a master of international legal studies degree from the Moscow State Institute of International Relations and a master of laws degree from the University of Virginia Law School.
- Jeffrey D. Abbey
-
2010年2月以来，Jeffrey D. Abbey担任我们的总裁、首席执行官、董事会成员。从2002年9月到2010年2月，他担任其他职位，包括从2004年2月到2004年1月，他担任我们的业务发展副总裁。从2009年1月至2010年2月，担任业务董事。在加入我们之前，从1999年到2001年，他担任业务发展和互联网应用网络方面的金融副总裁，一家信息技术公司。从1994年到1999年，他担任Eilenberg 和Krause合伙人，一家律师事务所企业。他拥有布朗大学数理经济学A.B以及弗吉尼亚大学法学博士学位和MBA。
Jeffrey D. Abbey has served as our president and chief executive officer and a member of our board of directors since February 2010. Mr. Abbey served in various other positions at our company from September 2002 to February 2010 including as our vice president of business development from February 2004 to January 2009 and as our chief business officer from January 2009 to February 2010. Prior to joining us, Mr. Abbey served as vice president of business development and finance at Internet Appliance Network, an information technology company, from 1999 to 2001. Mr. Abbey was a partner at Eilenberg and Krause, LLP, a corporate law firm, from 1994 to 1999. Mr. Abbey received an A.B. in mathematical economics from Brown University and an M.B.A. and J.D. from the University of Virginia. - 2010年2月以来，Jeffrey D. Abbey担任我们的总裁、首席执行官、董事会成员。从2002年9月到2010年2月，他担任其他职位，包括从2004年2月到2004年1月，他担任我们的业务发展副总裁。从2009年1月至2010年2月，担任业务董事。在加入我们之前，从1999年到2001年，他担任业务发展和互联网应用网络方面的金融副总裁，一家信息技术公司。从1994年到1999年，他担任Eilenberg 和Krause合伙人，一家律师事务所企业。他拥有布朗大学数理经济学A.B以及弗吉尼亚大学法学博士学位和MBA。
- Jeffrey D. Abbey has served as our president and chief executive officer and a member of our board of directors since February 2010. Mr. Abbey served in various other positions at our company from September 2002 to February 2010 including as our vice president of business development from February 2004 to January 2009 and as our chief business officer from January 2009 to February 2010. Prior to joining us, Mr. Abbey served as vice president of business development and finance at Internet Appliance Network, an information technology company, from 1999 to 2001. Mr. Abbey was a partner at Eilenberg and Krause, LLP, a corporate law firm, from 1994 to 1999. Mr. Abbey received an A.B. in mathematical economics from Brown University and an M.B.A. and J.D. from the University of Virginia.
- Hubert Birner
-
自2005年以来，Hubert Birner担任我们董事会主席。自2001年以来，他担任我们董事会的成员。一家风险资本公司，Argos的子公司。2000年，他担任投资经理。目前，他担任公司的管理合伙人。从1998年到2000年，他担任欧洲业务开发负责人和德国营销董事，捷利康农药公司，一家生物制药公司。加入Zeneca Agrochemicals之前，他担任McKinsey & Company和管理顾问，负责欧洲医疗和制药业务。他目前是Proteon Therapeutics和SpePharm Holdings BV董事会成员。此前，他担任Horizon Pharma、Bioxell SA, Evotec AG 和Jerini AG董事会成员。他拥有哈佛商学院MBA和德国慕尼黑大学生物化学博士学位。他的博士论文因在代谢疾病方面杰出的基础研究被授予Hoffmann-La Roche奖。
Hubert Birner joined the supervisory board of Centogene as Chairman from July 2017 to March 30 2019 and as Vice-Chairman from April 1 2019 to March 16 2020. He currently serves as a managing partner at TVM Capital, and is responsible for its overall investment strategy and fund operations in North American and Europe. Dr. Birner joined TVM Capital in 2000 as an investment manager. He currently also serves as Chairman of the supervisory board of SpePharm Holding B.V., leon-nanodrugs GmbH and AL-S Pharma AG. He is a member of the board of directors of Argos Therapeutics, Inc., Proteon Therapeutics Inc, Noxxon Pharma and Acer Therapeutics Inc. Dr. Birner previously served on the board of directors of Horizon Pharma, Inc., Bioxell SA, Evotec AG, Probiodrug AG and Jerini AG. Prior to his current tenure, he was Head of Business Development Europe and Director of Marketing for Germany at Zeneca Agrochemicals. Dr. Birner joined Zeneca from McKinsey & Company's European Health Care and Pharmaceutical practice and as Assistant Professor for biochemistry at the Ludwig-Maximilian-University "LMU". He holds a summa cum laude doctoral degree in biochemistry at LMU. His doctoral thesis was honored with the Hoffmann-La Roche prize for outstanding basic research in metabolic diseases. Dr. Birner also holds an MBA from Harvard Business School. - 自2005年以来，Hubert Birner担任我们董事会主席。自2001年以来，他担任我们董事会的成员。一家风险资本公司，Argos的子公司。2000年，他担任投资经理。目前，他担任公司的管理合伙人。从1998年到2000年，他担任欧洲业务开发负责人和德国营销董事，捷利康农药公司，一家生物制药公司。加入Zeneca Agrochemicals之前，他担任McKinsey & Company和管理顾问，负责欧洲医疗和制药业务。他目前是Proteon Therapeutics和SpePharm Holdings BV董事会成员。此前，他担任Horizon Pharma、Bioxell SA, Evotec AG 和Jerini AG董事会成员。他拥有哈佛商学院MBA和德国慕尼黑大学生物化学博士学位。他的博士论文因在代谢疾病方面杰出的基础研究被授予Hoffmann-La Roche奖。
- Hubert Birner joined the supervisory board of Centogene as Chairman from July 2017 to March 30 2019 and as Vice-Chairman from April 1 2019 to March 16 2020. He currently serves as a managing partner at TVM Capital, and is responsible for its overall investment strategy and fund operations in North American and Europe. Dr. Birner joined TVM Capital in 2000 as an investment manager. He currently also serves as Chairman of the supervisory board of SpePharm Holding B.V., leon-nanodrugs GmbH and AL-S Pharma AG. He is a member of the board of directors of Argos Therapeutics, Inc., Proteon Therapeutics Inc, Noxxon Pharma and Acer Therapeutics Inc. Dr. Birner previously served on the board of directors of Horizon Pharma, Inc., Bioxell SA, Evotec AG, Probiodrug AG and Jerini AG. Prior to his current tenure, he was Head of Business Development Europe and Director of Marketing for Germany at Zeneca Agrochemicals. Dr. Birner joined Zeneca from McKinsey & Company's European Health Care and Pharmaceutical practice and as Assistant Professor for biochemistry at the Ludwig-Maximilian-University "LMU". He holds a summa cum laude doctoral degree in biochemistry at LMU. His doctoral thesis was honored with the Hoffmann-La Roche prize for outstanding basic research in metabolic diseases. Dr. Birner also holds an MBA from Harvard Business School.
- Sander van Deventer
-
自2001年以来，Sander van Deventer一直是我们公司的董事会成员。从2006年开始，Dr. van Devente一直是Forbion Capital Partners公司原荷兰资本银行的合伙人。1998年，他跟人合作创立了阿姆斯特丹分子治疗中心，并在2008年到2009年，担任该治疗中心的执行总裁。自2007年起，他还担任过AMT的董事会成员。2008年他还在莱顿大学担任了平移消化内科的教授。同时他取得了阿姆斯特丹大学的医学博士和哲学博士学位。
Sander van Deventer has served as a member of our board of directors since October 2011. Dr. van Deventer has been a general partner of Forbion Capital Partners formerly ABN AMRO Capital since 2006. He has also been the Chief Scientific Officer of uniQure since August 2018. From 2008 to 2009 he served as the Chief Executive Officer of Amsterdam Molecular Therapeutics, or AMT, a gene therapy company that he co-founded in 1998. From 2012 to 2013 he was the Chief Executive Officer of Dezima Pharma, which was acquired by Amgen Inc. In addition, Dr. van Deventer has also served as a member of AMT's board of directors since 2007. He previously served as a member of the board of directors of Argos Therapeutics, Inc. from 2001 until 2018 and a member of the board of directors of uniQure from February 2014 until August 2018. Dr. van Deventer has also served as a professor of translational gastroenterology at Leiden University since 2008. He received an M.D. and Ph.D. from the University of Amsterdam. - 自2001年以来，Sander van Deventer一直是我们公司的董事会成员。从2006年开始，Dr. van Devente一直是Forbion Capital Partners公司原荷兰资本银行的合伙人。1998年，他跟人合作创立了阿姆斯特丹分子治疗中心，并在2008年到2009年，担任该治疗中心的执行总裁。自2007年起，他还担任过AMT的董事会成员。2008年他还在莱顿大学担任了平移消化内科的教授。同时他取得了阿姆斯特丹大学的医学博士和哲学博士学位。
- Sander van Deventer has served as a member of our board of directors since October 2011. Dr. van Deventer has been a general partner of Forbion Capital Partners formerly ABN AMRO Capital since 2006. He has also been the Chief Scientific Officer of uniQure since August 2018. From 2008 to 2009 he served as the Chief Executive Officer of Amsterdam Molecular Therapeutics, or AMT, a gene therapy company that he co-founded in 1998. From 2012 to 2013 he was the Chief Executive Officer of Dezima Pharma, which was acquired by Amgen Inc. In addition, Dr. van Deventer has also served as a member of AMT's board of directors since 2007. He previously served as a member of the board of directors of Argos Therapeutics, Inc. from 2001 until 2018 and a member of the board of directors of uniQure from February 2014 until August 2018. Dr. van Deventer has also served as a professor of translational gastroenterology at Leiden University since 2008. He received an M.D. and Ph.D. from the University of Amsterdam.
- Robert F. Carey
-
Robert F. Carey于2019年2月加入Beyond Air，Inc.董事会。他帮助生物技术和专业制药公司通过首次公开发行、后续发行、债务发行和私募融资筹集了超过100亿美元。他曾担任并购和战略联盟交易的财务顾问，总交易价值超过100亿美元。Carey先生共同创立了ACELYRIN，Inc.，并担任该公司的总裁兼首席运营官，该公司是一家生物制药公司，将投资、开发和商业化改变生命的药物疗法。Carey先生曾于2014年3月至2019年9月担任Horizon Therapeutics plc的执行副总裁兼首席业务官，在此期间，Horizon therrapeutics斥资超过35亿美元收购或许可了8种商业产品和3种正在开发的产品，净销售额从2013年的7400万美元增长至2018年的约12亿美元，复合年增长率为75%。在Horizon之前，他曾在JMP证券担任常务董事兼生命科学投资银行集团负责人超过11年。Carey先生还是Dresdner Kleinwort Wasserstein和Vector Securities医疗集团的董事总经理。他在圣母大学获得会计学学士学位。Carey先生目前担任Sangamo Therapeutics，Inc.股份有限公司和Hawthorne Race Course，Inc.股份有限公司的董事会成员，并曾于2020年7月至2021年2月担任双子治疗学股份有限公司的Disk Medicine，Inc.董事会成员。
Robert F. Carey,joined Beyond Air, Inc. Board of Directors in February 2019. He has an extensive track record of accomplishment within the biopharmaceutical and healthcare investment banking industry. He has assisted biotech and specialty pharma companies raise more than $10 billion in initial public offerings, follow-on offerings, debt offerings, and private placements. He has served as a financial advisor on mergers, acquisitions, and strategic alliance transactions with a total deal value of more than $10 billion. Mr. Carey is a co-founder and from July 2020 until December 2022 was President of ACELYRIN, INC., a biopharmaceutical company developing life-changing drug therapies.Mr. Carey previously served as Executive Vice President and Chief Business Officer at Horizon Therapeutics plc from March 2014 to September 2019, during which Horizon Therapeutics deployed in excess of $3.5 billion to acquire or license eight commercial products and three products in development and grew net sales from $74 million in 2013 to approximately $1.2 billion in 2018, a compound annual growth rate of 75%. Before Horizon, he spent more than 11 years as Managing Director and Head of the Life Sciences Investment Banking Group at JMP Securities. Mr. Carey was also Managing Director in the healthcare groups at Dresdner Kleinwort Wasserstein and Vector Securities. He received his B.B.A. in Accounting from the University of Notre Dame. Mr. Carey currently serves on the Board of Beyond Cancer Ltd. and Sangamo Therapeutics, Inc. - Robert F. Carey于2019年2月加入Beyond Air，Inc.董事会。他帮助生物技术和专业制药公司通过首次公开发行、后续发行、债务发行和私募融资筹集了超过100亿美元。他曾担任并购和战略联盟交易的财务顾问，总交易价值超过100亿美元。Carey先生共同创立了ACELYRIN，Inc.，并担任该公司的总裁兼首席运营官，该公司是一家生物制药公司，将投资、开发和商业化改变生命的药物疗法。Carey先生曾于2014年3月至2019年9月担任Horizon Therapeutics plc的执行副总裁兼首席业务官，在此期间，Horizon therrapeutics斥资超过35亿美元收购或许可了8种商业产品和3种正在开发的产品，净销售额从2013年的7400万美元增长至2018年的约12亿美元，复合年增长率为75%。在Horizon之前，他曾在JMP证券担任常务董事兼生命科学投资银行集团负责人超过11年。Carey先生还是Dresdner Kleinwort Wasserstein和Vector Securities医疗集团的董事总经理。他在圣母大学获得会计学学士学位。Carey先生目前担任Sangamo Therapeutics，Inc.股份有限公司和Hawthorne Race Course，Inc.股份有限公司的董事会成员，并曾于2020年7月至2021年2月担任双子治疗学股份有限公司的Disk Medicine，Inc.董事会成员。
- Robert F. Carey,joined Beyond Air, Inc. Board of Directors in February 2019. He has an extensive track record of accomplishment within the biopharmaceutical and healthcare investment banking industry. He has assisted biotech and specialty pharma companies raise more than $10 billion in initial public offerings, follow-on offerings, debt offerings, and private placements. He has served as a financial advisor on mergers, acquisitions, and strategic alliance transactions with a total deal value of more than $10 billion. Mr. Carey is a co-founder and from July 2020 until December 2022 was President of ACELYRIN, INC., a biopharmaceutical company developing life-changing drug therapies.Mr. Carey previously served as Executive Vice President and Chief Business Officer at Horizon Therapeutics plc from March 2014 to September 2019, during which Horizon Therapeutics deployed in excess of $3.5 billion to acquire or license eight commercial products and three products in development and grew net sales from $74 million in 2013 to approximately $1.2 billion in 2018, a compound annual growth rate of 75%. Before Horizon, he spent more than 11 years as Managing Director and Head of the Life Sciences Investment Banking Group at JMP Securities. Mr. Carey was also Managing Director in the healthcare groups at Dresdner Kleinwort Wasserstein and Vector Securities. He received his B.B.A. in Accounting from the University of Notre Dame. Mr. Carey currently serves on the Board of Beyond Cancer Ltd. and Sangamo Therapeutics, Inc.
高管简历
中英对照 | 中文 | 英文- Richard D. Katz
- 暂无中文简介
Richard D. Katz has served as our vice president and chief financial officer since July 2016. Prior to joining us, Dr. Katz served as chief financial officer for Viamet Pharmaceuticals, Inc., a biotechnology company, from February 2011 to May 2016. Dr. Katz also served as chief financial officer at Icagen, Inc., a biotechnology company, from April 2001 to November 2011. Prior to Icagen, Dr. Katz served as a vice president in the healthcare group at Goldman, Sachs & Company. Dr. Katz received an A.B. magna cum laude from Harvard University, an M.D. from the Stanford University School of Medicine and an M.B.A. from Harvard Business School. - 暂无中文简介
- Richard D. Katz has served as our vice president and chief financial officer since July 2016. Prior to joining us, Dr. Katz served as chief financial officer for Viamet Pharmaceuticals, Inc., a biotechnology company, from February 2011 to May 2016. Dr. Katz also served as chief financial officer at Icagen, Inc., a biotechnology company, from April 2001 to November 2011. Prior to Icagen, Dr. Katz served as a vice president in the healthcare group at Goldman, Sachs & Company. Dr. Katz received an A.B. magna cum laude from Harvard University, an M.D. from the Stanford University School of Medicine and an M.B.A. from Harvard Business School.
- Jeffrey D. Abbey
2010年2月以来，Jeffrey D. Abbey担任我们的总裁、首席执行官、董事会成员。从2002年9月到2010年2月，他担任其他职位，包括从2004年2月到2004年1月，他担任我们的业务发展副总裁。从2009年1月至2010年2月，担任业务董事。在加入我们之前，从1999年到2001年，他担任业务发展和互联网应用网络方面的金融副总裁，一家信息技术公司。从1994年到1999年，他担任Eilenberg 和Krause合伙人，一家律师事务所企业。他拥有布朗大学数理经济学A.B以及弗吉尼亚大学法学博士学位和MBA。
Jeffrey D. Abbey has served as our president and chief executive officer and a member of our board of directors since February 2010. Mr. Abbey served in various other positions at our company from September 2002 to February 2010 including as our vice president of business development from February 2004 to January 2009 and as our chief business officer from January 2009 to February 2010. Prior to joining us, Mr. Abbey served as vice president of business development and finance at Internet Appliance Network, an information technology company, from 1999 to 2001. Mr. Abbey was a partner at Eilenberg and Krause, LLP, a corporate law firm, from 1994 to 1999. Mr. Abbey received an A.B. in mathematical economics from Brown University and an M.B.A. and J.D. from the University of Virginia.- 2010年2月以来，Jeffrey D. Abbey担任我们的总裁、首席执行官、董事会成员。从2002年9月到2010年2月，他担任其他职位，包括从2004年2月到2004年1月，他担任我们的业务发展副总裁。从2009年1月至2010年2月，担任业务董事。在加入我们之前，从1999年到2001年，他担任业务发展和互联网应用网络方面的金融副总裁，一家信息技术公司。从1994年到1999年，他担任Eilenberg 和Krause合伙人，一家律师事务所企业。他拥有布朗大学数理经济学A.B以及弗吉尼亚大学法学博士学位和MBA。
- Jeffrey D. Abbey has served as our president and chief executive officer and a member of our board of directors since February 2010. Mr. Abbey served in various other positions at our company from September 2002 to February 2010 including as our vice president of business development from February 2004 to January 2009 and as our chief business officer from January 2009 to February 2010. Prior to joining us, Mr. Abbey served as vice president of business development and finance at Internet Appliance Network, an information technology company, from 1999 to 2001. Mr. Abbey was a partner at Eilenberg and Krause, LLP, a corporate law firm, from 1994 to 1999. Mr. Abbey received an A.B. in mathematical economics from Brown University and an M.B.A. and J.D. from the University of Virginia.
- Lori R. Harrelson
Lori R. Harrelson自2011年7月以来，担任我们的财务副总裁。从2007年1月至2011年7月，她担任我们的财务和会计董事。从2004年9月到2007年1月，她担任我们会计和财务报告董事。她在加入我们之前，从2001年到2004年，她在LipoScience公司担任财务经理，一家诊断公司。她获得东卡罗莱纳大学金融学学士学位和C.P.A.。
Lori R. Harrelson has served as our vice president of finance since July 2011. Ms. Harrelson served as our director of finance and accounting from January 2007 to July 2011 and as our director of accounting and financial reporting from September 2004 to January 2007. Prior to joining us, Ms. Harrelson served as finance manager at LipoScience, Inc., a diagnostic company, from 2001 to 2004 and a senior auditor at Ernst & Young, from 1997 to 2001. Ms. Harrelson received a B.S. in finance from East Carolina University and is a C.P.A.- Lori R. Harrelson自2011年7月以来，担任我们的财务副总裁。从2007年1月至2011年7月，她担任我们的财务和会计董事。从2004年9月到2007年1月，她担任我们会计和财务报告董事。她在加入我们之前，从2001年到2004年，她在LipoScience公司担任财务经理，一家诊断公司。她获得东卡罗莱纳大学金融学学士学位和C.P.A.。
- Lori R. Harrelson has served as our vice president of finance since July 2011. Ms. Harrelson served as our director of finance and accounting from January 2007 to July 2011 and as our director of accounting and financial reporting from September 2004 to January 2007. Prior to joining us, Ms. Harrelson served as finance manager at LipoScience, Inc., a diagnostic company, from 2001 to 2004 and a senior auditor at Ernst & Young, from 1997 to 2001. Ms. Harrelson received a B.S. in finance from East Carolina University and is a C.P.A.
- Charles A. Nicolette
自2007年12月以来，Charles A. Nicolette担任我们的首席科学官。自2004年12月以来，他担任我们研究和开发的副总裁。从2003年7月到2004年12月，他担任我们研发部的副总裁。在加入我们之前，从1997年到2003年，他在 Genzyme Molecular Oncology公司担任过各种职务，一家生物技术公司。最近，他担任Antigen Discovery主管。他拥有纽约州立大学石溪分校理学学士学位和纽约州立大学石溪分校生物化学、细胞和发育生物学的博士学位，他在冷泉港实验室完成他的博士论文并获得博士后奖学金。
Charles A. Nicolette has served as our chief scientific officer since December 2007 and as our vice president of research and development since December 2004. Dr. Nicolette served as our vice president of research from July 2003 to December 2004. Prior to joining us, Dr. Nicolette served in various positions at Genzyme Molecular Oncology, Inc., a biotechnology company, from 1997 to 2003 most recently as director of antigen discovery. Dr. Nicolette received a B.S. from the State University of New York at Stony Brook and a Ph.D. in biochemistry and cellular and developmental biology from the State University of New York at Stony Brook, completing his doctoral dissertation and post-doctoral fellowship at Cold Spring Harbor Laboratory.- 自2007年12月以来，Charles A. Nicolette担任我们的首席科学官。自2004年12月以来，他担任我们研究和开发的副总裁。从2003年7月到2004年12月，他担任我们研发部的副总裁。在加入我们之前，从1997年到2003年，他在 Genzyme Molecular Oncology公司担任过各种职务，一家生物技术公司。最近，他担任Antigen Discovery主管。他拥有纽约州立大学石溪分校理学学士学位和纽约州立大学石溪分校生物化学、细胞和发育生物学的博士学位，他在冷泉港实验室完成他的博士论文并获得博士后奖学金。
- Charles A. Nicolette has served as our chief scientific officer since December 2007 and as our vice president of research and development since December 2004. Dr. Nicolette served as our vice president of research from July 2003 to December 2004. Prior to joining us, Dr. Nicolette served in various positions at Genzyme Molecular Oncology, Inc., a biotechnology company, from 1997 to 2003 most recently as director of antigen discovery. Dr. Nicolette received a B.S. from the State University of New York at Stony Brook and a Ph.D. in biochemistry and cellular and developmental biology from the State University of New York at Stony Brook, completing his doctoral dissertation and post-doctoral fellowship at Cold Spring Harbor Laboratory.
- Richard D. Katz
自2019年5月以来，RichardD.Katz一直是我们的首席财务官。他曾担任ArgosTherapeutics，Inc.的Vice President和首席财务官纳斯达克:ARGS，一家免疫疗法开发公司，自2016年7月至2018年11月，Argos Therapeutics根据第11章向特拉华州破产法院提交了救济请愿书，并于2018年11月至2019年5月担任Argos Therapeutics的顾问。在加入Argos Therapeutics之前，Katz博士于2012年2月至2016年5月担任生物制药公司Viamet Pharmaceuticals，Inc.的首席财务官。2001年4月至2011年11月，Katz博士还担任生物制药公司Icagen，Inc.（纳斯达克市场代码:ICGN）的首席财务官，他在该公司的首次公开募股和随后的融资、几项战略合作的形成以及该公司出售给辉瑞公司方面发挥了重要作用。任职Icagen公司之前，他曾担任Goldman，Sachs&Company的投资银行部门的梦百合集团的Vice President，在那里他曾执行多种交易，包括股权和债务融资、并购和公司重组。Katz博士在哈佛大学（Harvard University）获得文学学士学位，在斯坦福大学医学院（Stanford University School of Medicine）获得医学学位并在哈佛商学院（Harvard Business School）获得工商管理硕士学位。
Richard D. Katz has been our Chief Financial Officer since May 2019. He served as Vice President and Chief Financial Officer of Argos Therapeutics, Inc. Nasdaq: ARGS, an immunotherapy development company, from July 2016 until November 2018 when Argos Therapeutics filed a petition for relief under chapter 11 in the Bankruptcy Court for the District of Delaware, and served as a consultant to Argos Therapeutics from November 2018 until May 2019. Prior to joining Argos Therapeutics, Dr. Katz served as Chief Financial Officer for Viamet Pharmaceuticals, Inc., a biopharmaceutical company, from February 2012 to May 2016. Dr. Katz also served as Chief Financial Officer at Icagen, Inc. (Nasdaq: ICGN), a biopharmaceutical company, from April 2001 to November 2011 where he was instrumental in the company's initial public offering and subsequent financings, the formation of several strategic collaborations, and the company's sale to Pfizer. Prior to Icagen, Dr. Katz served as a Vice President in the healthcare group of the investment banking division of Goldman, Sachs & Company, where he executed a broad range of transactions, including equity and debt financings, mergers and acquisitions, and corporate restructurings. Dr. Katz received a Bachelor of Arts degree from Harvard University, a medical degree from the Stanford University School of Medicine and an MBA from Harvard Business School.- 自2019年5月以来，RichardD.Katz一直是我们的首席财务官。他曾担任ArgosTherapeutics，Inc.的Vice President和首席财务官纳斯达克:ARGS，一家免疫疗法开发公司，自2016年7月至2018年11月，Argos Therapeutics根据第11章向特拉华州破产法院提交了救济请愿书，并于2018年11月至2019年5月担任Argos Therapeutics的顾问。在加入Argos Therapeutics之前，Katz博士于2012年2月至2016年5月担任生物制药公司Viamet Pharmaceuticals，Inc.的首席财务官。2001年4月至2011年11月，Katz博士还担任生物制药公司Icagen，Inc.（纳斯达克市场代码:ICGN）的首席财务官，他在该公司的首次公开募股和随后的融资、几项战略合作的形成以及该公司出售给辉瑞公司方面发挥了重要作用。任职Icagen公司之前，他曾担任Goldman，Sachs&Company的投资银行部门的梦百合集团的Vice President，在那里他曾执行多种交易，包括股权和债务融资、并购和公司重组。Katz博士在哈佛大学（Harvard University）获得文学学士学位，在斯坦福大学医学院（Stanford University School of Medicine）获得医学学位并在哈佛商学院（Harvard Business School）获得工商管理硕士学位。
- Richard D. Katz has been our Chief Financial Officer since May 2019. He served as Vice President and Chief Financial Officer of Argos Therapeutics, Inc. Nasdaq: ARGS, an immunotherapy development company, from July 2016 until November 2018 when Argos Therapeutics filed a petition for relief under chapter 11 in the Bankruptcy Court for the District of Delaware, and served as a consultant to Argos Therapeutics from November 2018 until May 2019. Prior to joining Argos Therapeutics, Dr. Katz served as Chief Financial Officer for Viamet Pharmaceuticals, Inc., a biopharmaceutical company, from February 2012 to May 2016. Dr. Katz also served as Chief Financial Officer at Icagen, Inc. (Nasdaq: ICGN), a biopharmaceutical company, from April 2001 to November 2011 where he was instrumental in the company's initial public offering and subsequent financings, the formation of several strategic collaborations, and the company's sale to Pfizer. Prior to Icagen, Dr. Katz served as a Vice President in the healthcare group of the investment banking division of Goldman, Sachs & Company, where he executed a broad range of transactions, including equity and debt financings, mergers and acquisitions, and corporate restructurings. Dr. Katz received a Bachelor of Arts degree from Harvard University, a medical degree from the Stanford University School of Medicine and an MBA from Harvard Business School.